Sangamo Therapeutics Inc
Fermé
SecteurSoins de santé
0.17
Résumé
Variation du prix de l'action
24h
Min
0.17
Max
0.17
Revenu | -2.5M -37M |
|---|---|
Ventes | 14M 14M |
BPA | -0.111 |
Marge bénéficiaire | -262.996 |
Employés | 142 |
EBITDA | 10M -23M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +4900% upside |
Capitalisation Boursière | -51M 74M |
|---|---|
Ouverture précédente | 0.17 |
Clôture précédente | 0.17 |
Score Technique
By Trading Central
Confiance
Strong Bearish Evidence
Sangamo Therapeutics Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Sangamo Therapeutics Inc prévision
Objectif de Prix
By TipRanks
4900% hausse
Prévisions sur 12 Mois
Moyen 6 USD 4900%
Haut 10 USD
Bas 2 USD
Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
$
À Propos Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
